retatrutide triple agonist glp-1 gip glucagon ly3437943 is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials Capsule Bundle Abstract 4129733: Glucagon-like Peptide Size:18 Pack

retatrutide triple agonist glp-1 gip glucagon ly3437943 is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials Capsule Bundle Abstract 4129733: Glucagon-like Peptide Size:18 Pack

Abstract 4129733: Glucagon-like Peptide 1 Receptor Agonists Effect on Low-Density Lipoprotein Cholesterol and Total Cholesterol Levels Independent of Weight Reduction: A Meta-analysis and Meta-regression of Placebo-controlled Randomized Controlled ...

10.1038/s41598-021-94595-6 68 MurakamiT.FujimotoH.InagakiN

Capsule Bundle

Size:18 Pack

Several drugs are in advanced clinical trials: • In Phase III trials: IBI362 (Innovent/Eli Lilly), CagriSema (Novo Nordisk), Retatrutide (Eli Lilly), and Survodutide (Boehringer Ingelheim)